CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a co

Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new I

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with pl

Agios Pharmaceuticals NASDAQ: AGIO used an investor webcast tied to the 2026 European Hematology Ass

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with pl

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and l

Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic

Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-gene

Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficac

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on d

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agre

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

Agios Pharmaceuticals said on Friday ​it will stop developing its ‌experimental drug for a form of b

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was wel

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was wel

Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the

AMSTERDAM--(BUSINESS WIRE)-- #Avanzanite--Avanzanite Bioscience B.V., a rapidly growing commercial-s

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on d

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-trans

Agios Pharmaceuticals NASDAQ: AGIO executives said the company is focused on advancing mitapivat acr

AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on d

sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated a

Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which beat the an

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and r

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutra

.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on d

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a

U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can